Merck (MRK) is reportedly planning to double the production of molnupiravir, an antiviral COVID pill, next year. The Financial Times reported the drugmaker has secured deals to provide COVID ...

The green light means that Paxlovid – based on nirmatrelvir (formerly PF-07321332) and ritonavir – has been cleared for use in the US ahead of rival therapy molnupiravir from Merck & Co and ...

Ridgeback and Merck have partnered to develop molnupiravir and will share profits. In some of the children Denison treats as the director of pediatric infectious diseases at VUMC, remdesivir ...

While Merck's oral drug Molnupiravir has already been cleared by the United Kingdom to treat COVID-19, a Paraguayan laboratory has filed for its emergency registration in the South American ...

Molnupiravir was developed by Merck, Sharp and Dohme and Ridgeback Biotherapeutics. Merck explained that in clinical trials, Molnupiravir was administered to 775 patients who had recently been ...

Merck has already reported interim phase 2/3 results with molnupiravir which showed the drug could reduce the time taken for patients with symptomatic COVID-19 to have a negative SARS-CoV-2 swab test.

The new anti-viral drug brought out by Merck Pharmaceuticals, Molnupiravir, seems to be a promising development in the global fight against COVID-19. Early results from the phase-3 trial of the ...

The government agreed last month to pay Merck and its partner Ridgeback Biotherapeutics about $1.2 billion for 1.6 million courses of their drug molnupiravir. In addition, Kishida announced last ...

Amid the ongoing resurgence of new Covid-19 cases in India, an expert panel of the Central Drugs Standard Control Organisation on Tuesday approved Merck's anti-viral drug molnupiravir for ...